Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 16Vincristine 12Prednisone 11Methotrexate 11Etoposide 9Cytarabine 9merphos 8blinatumomab 8venetoclax 7prednylidene 7pegaspargase 7deltacortene 7Specimen Handling 7Mercaptopurine 7Dexamethasone 7azathiopurine 6N,N-dicyclohexyl-isoborneol-10-sulfonamide 6Doxorubicin 6Calcium Dobesilate 6dexamethasone acetate 5dexamethasone 21-phosphate 5auricularum 5Spinal Puncture 5Rituximab 5Leucovorin 5Biopsy 5fludarabine phosphate 4Stem Cell Transplantation 4Methylprednisolone 4Inotuzumab Ozogamicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Burkitt Lymphoma × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT04148430 2025-11-05

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
62 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡